[1] 李铭,廖红,程恒辉. 苦参素对人肺癌A549细胞增殖及caspase3/7蛋白活性的影响[J]. 细胞与分子免疫学杂志,2013,29(5):498-499.
[2] 张治业,高晓会,郭双双,等. 苦参素注射液联合NP方案治疗老年晚期NSCLC近期疗效观察[J]. 山东医药,2011,51(26):100-101.
[3] 郭柳薇,高兴华,黄王莹. 肺癌患者6种血清肿瘤标志物检测结果分析[J]. 江苏医药,2014,40(1):69-71.
[4] Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib[J]. Anticancer Res, 2014, 34(6):3205-3210.
[5] 王敏. 血清VEGF、TGF-β1及内皮抑素在非小细胞肺癌中的表达及相关性研究[J]. 检验医学, 2013,28(8):676-680.
[6] Deng B, Tan QY, Fan XQ, et al. Clinical value of assaying tumor supplied group of factor/tumor specific growth factor in patients with solitary pulmonary nodule[J]. Clin Lung Cancer, 2011, 12(3):192-196.
[7] Xue Y, Wu L, Liu Y, et al. Entpd5 induces apoptosis in lung cancer cells via regulating caspase 3 expression[J]. PLoS One, 2015, 10(3):e0120046.
[8] Lin YF, Lai TC, Chang CK, et al. Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies[J]. J Clin Invest, 2013, 123(9):3861-3875.
[9] 邓伟,吴一龙. 促凋亡蛋白Bim在肺癌中的研究进展[J]. 肿瘤防治研究,2014,41(11):1247-1250.
[10] Siena L, Pace E, Ferraro M, et al. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing[J]. Immunology, 2014, 141(2):242-255.
[11] Jin Y, Tong DY, Tang LY, et al. Expressions of Osteopontin (OPN), αvβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)[J]. Chin J Cancer Res, 2012, 24(2):103-108.
[12] 左慧敏,曾林祥. Wnt信号通路与非小细胞肺癌的研究进展[J]. 基础医学与临床,2015,35(2):266-269.
[13] Zhang X, Lou Y, Wang H, et al. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells[J]. Med Oncol, 2015, 32(4):95.
[14] Hu Y, Hong Y, Xu Y, et al. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer (NSCLC)[J]. Apoptosis, 2014, 19(11):1627-1636.
[15] 伊庆强,赵美,王炯轶,等. 抑制JAK2/STAT3信号通路对肺癌细胞A549中HIF-1α、VEGF和miRNA-145表达的影响[J]. 上海交通大学学报(医学版),2014,34(7):1011-1016.